Nurix Therapeutics Q3 2024 GAAP EPS $(0.67) Beats $(0.70) Estimate, Sales $12.588M Miss $13.248M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics reported a Q3 2024 GAAP EPS of $(0.67), beating the estimate of $(0.70), but sales of $12.588M missed the $13.248M estimate. Sales decreased by 31.84% compared to the same period last year.
October 11, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Nurix Therapeutics' Q3 2024 earnings per share beat expectations, but sales fell short and decreased significantly year-over-year.
The EPS beat suggests better-than-expected cost management or other financial efficiencies, which is positive. However, the sales miss and significant year-over-year decline indicate potential challenges in revenue generation, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100